This trial showed that propranolol was effective at a dose of 3 mg per kilogram per day for 6 months in the treatment of infantile hemangioma. (Funded by Pierre Fabre Dermatologie; ClinicalTrials.gov number, NCT01056341.).

BACKGROUND AND OBJECTIVES: Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this review were to evaluate the safety profile of oral propranolol in the treatment of IH.

The overall prevalence of self-reported acne was high in adolescents/young adults in the European countries investigated. Heredity was the main risk factor for developing acne.

Long-term therapy with emollient is effective and well tolerated for the treatment of xerosis in children with atopic dermatitis.

Infantile hemangioma is a vascular tumor characterized by rapid growth during the first weeks of life and spontaneous involution over a few years. 1 Severe forms require systemic therapy. Propranolol induces regression, but safety data are lacking in children. 2,3